Unwanted Immunology

M.V. Supotnytskyi

Abstract


The paper considers the role of antigenic imprin­ting phenomena and antibody-dependent enhancement of infection in epidemic, infectious and postvaccinal processes. Based on published experimental data, it is shown that both phenomena are directly related to the laws of development and course of epide­mics, the pathogenesis of infectious diseases and safe use of vaccines. Their ignoring by researchers has led to failures in the design of vaccines against HIV/AIDS, dengue fever, influenza, malaria, hemorrhagic fever and encephalitis. These data show that, without taking into account the two phenomena, the further development of immunology and epidemiology in the direction of breakthrough discoveries in there areas of science are impossible.


Keywords


phenomenon of the original antigenic sin; anamnestic response; antigenic imprinting; immunoglobulin; antibody; swine flu; flu; vaccine; viral protein; phenomenon of antibody-dependent enhancement of infection; complement; cross-reactive antibodies

References


Богадельников И.В. Микроорганизмы — ​властители эволюции. — ​Симферополь, 2016.

Борисов Л.Б. Медицинская микробиология, вирусология, иммунология. — ​М., 2001.

Воробьев А.А., Быков А.С., Пашков Е.П., Караулов А.В. Микробиология. — ​М., 1992.

Воробьев А.А. Не подводя черты. — ​М., 2003.

Галактионов В.Г. Эволюционная иммунология. — ​М., 2005.

Горбунова А.С. Грипп // Руководство по микробиологии, клинике и эпидемиологии инфекционных болезней / Под ред. Жданова В.М. — ​М.: Медицина, 1966. — ​Т. VIII. — ​С. 13-60.

Заболотный Д.К. Пустулезная форма чумы // Русский архив патологии. 1899. VIII: 239-42.

Исаева Е.И., Морозова О.В., Ветрова Е.Н., Вартанян Р.В., Козулина И.С. Детекция, идентификация и количественные оценки бокавируса у детей с острыми респираторными вирусными инфекциями и гастроэнтеритами в Москве. Живые и биокосные системы. — 2014. — 9. URL: http://www.jbks.ru/archive/issue‑9/article‑18.

Карпухин Г.И., Швецова Е.Г., Малышева А.М. Итоги многолетнего опыта изучения эффективности экстренной профилактики гриппа ремантадином в эпидемиологических наблюдениях // Проблемы гриппа и острых респираторных болезней. — ​Л., 1979. — ​С. 24-8

Константинова Н.А. Иммунные комплексы и повреждение тканей. — ​М., 1996.

Купер Э. Сравнительная иммунология. — ​М., 1980.

Норейко Б.В. Иммунологические аспекты фтизиатрии // Новости медицины и фармации. 2003; 2. URL: http://www.1796kotok.com/vaccines/malady/noreiko.htm.

Супотницкий М.В. Пандемия «испанки» 1918–1920 гг. в контексте других гриппозных пандемий и «птичьего гриппа» // Медицинская картотека. 2006; 11: 31-4; 12: 15-25, 28-30; 2007; 1: 16-22. URL: http://www.supotnitskiy.ru/stat/stat51.htm.

Супотницкий М.В. Эволюционная патология. — ​М., 2009.

Супотницкий М.В. Феномен антителозависимого усиления инфекции при доклиническом изучении иммунобиологических лекарственных препаратов // Руководство по проведению доклинических исследований лекарственных средств (иммунобиологические лекарственные препараты). Часть вторая / Под ред. Миронова А.Н. — ​М.: Гриф и К, 2012б. — ​C. 177-85.

Adalja A.A., Henderson D.A. Original antigenic sin and pandemic (H1N1) 2009 // Emerging Infectious Diseases. 2010; 16(6): 1028-9.

Angelova L., Shvartsman Y. Original antigenic sin to influenza in rats // Immunology. 1982; 46: 183-8.

Baldinotti F.D., Matteucci P., Mazzetti P., Giannelli C., Bandecchi P., Tozzini F., Bendinelli M. Serum neutralization of feline immunodeficiency virus is markedly dependent on passage history of the virus and host system // J. Virol. 1994; 74: 10834-7.

Balsitis S.J., Williams K.L., Lachica R., Flores D., Kyle J.L., Mehlhop E., Johnson S. et al. Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification // PLoS Pathog. 2010; 12.

Barrett A.D.T., Gould A. Antibody-mediated early death in vivo after infection with Yellow fever virus // J. Gen. Virol. 1986 (67): 2539-42.

Beltramello M., Williams K.L., Simmons C.P., Macagno A., Simonelli L., Quyen N.T. et al. The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity // Cell Host Microbe. 2010; 8: 271-83.

Blancou J., Andrai B., Andrai L. A model in mice for the study of the early death phenomenon after vaccination and challenge with rabies virus // J. Gen. Virol. 1980; 50: 433-5.

Broker M., Kollaritsch H. After a tick bite in a tick-borne encephalitis virus endemic area: current positions about post-exposure treatment // Vaccine. 2008; 26(7): 863-8.

Brown S.A., Surman S.L., Sealy R., Jones B.G., Slobod K.S., Branum K. et al. Heterologous prime-boost HIV‑1 vaccination regimens in pre-clinical and clinical trials // Viruses. 2010; 2(2): 435-67.

Burton D.R., Stanfield R.L., Wilson I.A. Antibody vs. HIV in a clash of evolutionary titans // Proc. Natl. Acad. Sci USA. 2005; 102(42): 14943-94.

Chaturvedi U.C., Raghupathy R., Pasca A.S. Shift from a Th1-type response to Th1-type in dengue haemorrhagic fever // Curr. Sci. 1999; 76: 63-9.

Choi Y.A., Baek Y.H., Kang W., Nam S.J., Lee J., You S. et al. Reduced antibody responses to the pandemic (H1N1) 2009 vaccine after recent seasonal influenza vaccination // Clin. Vaccine Immunol. 2011; 18(9): 1519-23.

Chowell G., Bertozzi S.M., Colchero А.M., Lopez-Gatell H., Alpuche-Aranda C., Hernandez M., Miller M.A. Severe respiratory disease concurrent with the circulation of H1N1 influenza // N. Engl. J. Med. 2009; 361: 674-9.

Couch R.B., Webster R.G., Kasel T.R., Cate T.R. Efficacy of purified influenza subunit vaccines and relation to the major antigenic determinants on the hemagglutinin molecule // J. Infect. Dis. 1979; 140: 553-9.

Crill W.D., Hughes H.R., Trainor N.B., Davis B.S., Whitney M.T., Chang G.J. Sculpting humoral immunity through dengue vaccination to enhance protective immunity // Frontiers in Immunology. 2012; 3: Art. 334.

Davenport F.M., Hennessy A.V., Francis T. Epidemiologic and immunologic significance of age distribution of antibody to antigenic variants of influenza virus // J. Exp. Med. 1953; 98: 641-56.

Davenport F.M., Hennessy A.V. A serologic recapitulation of past experience with influenza A; antibody response to monovalent vaccine // J. Exp. Med. 1956; 104: 85-97.

Dejnirattisai W., Jumnainsong A., Onsirisakul N. Cross-reacting antibodies enhance dengue virus infection in humans // Science. 2010; 328: 745-8.

Delgado M.F., Coviello S., Monsalvo A.C., Melendi G.A., Hernandez J.Z., Batalle J.P. et al. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease // Nat. Med. 2009; 15: 34-41.

Duangchindaa T., Dejnirattisaia W., Vasanawathanac S., Limpitikuld W., Tangthawornchaikulb N., Malasitb P. et al. Immunodominant T-cell responses to dengue virus NS3 are associated with DHF // Proc. Natl. Acad. Sci USA. 2010; 107(39): 16922-7.

Flingai S., Plummer E.M., Patel A., Shresta S., Mendoza J.M., Broderick K.E. et al. Protection against dengue disease by synthetic nucleic acid antibody prophylaxis/immunotherapy // Scientific Reports. 2015; 5: 12616. Dоі: 10.1038/srep12616.

Flipse J., Wilschut J., Smit J.M. Molecular mechanisms involved in antibody-dependent enhancement of Dengue virus infection in humans // Traffic. 2013; 14: 25-35.

Francis T. Influenza. The newe acquayantance // Ann. Int. Med. 1953; 399(3): 201-21.

Francis T. The current status of the control of influenza // Ann. Int. Med. 1955; 43: 534-8.

Frost S., Wrin T., Smith D.M., Kosakovsky S., Liu Y., Pa­xinos E. et al. Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection // Proc. Natl. Acad. Sci USA. 2005; 102(51): 18514-9.

Fulginiti F.A., Eller J.J., Downie A.W., Kempe C.H. Altered reactivity to measles virus. Atypical measles in children previously immunized with inactivated measles virus vaccines // JAMA. 1967 (202): 1075-80.

Fust G. Enhancing antibodies in HIV infection // Parasitol. 1997; 115(Suppl.): 127-40.

Gatherer D. The 2009 H1N1 influenza outbreak in its historical context // J. Clin. Virol. 2009; 45: 174-8.

Goulld E.A., Buckley A. Antibody-dependent enhancement of Yellow Fever and Japanese encephalitis virus neurovirulence // J. Gen. Virol. 1989; 70: 1605-8.

Halstead S.B., Chow J., Marchette N.J. Immunologic enhancement of Dengue virus replication // Nat. New Biol. 1973; 243: 24-6.

Halstead S.B., Rojanasuphot S., Sangkawibha N. Original antigenic sin in dengue // Am. J. Trop. Med. Hyg. 1983; 32: 154-6.

Halstead S.B., Mahalingam P.S., Marovich M.A., Ubol S., Mosser D.M. Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes // Lancet Infect Dis. 2010; 10(10): 712-22.

Han J.-F., Cao R., Deng Y., Tian X., Jiang T., Qin E.D., Qin C.F. Antibody dependent enhancement infection of Enterovirus 71 in vitro and in vivo // Virol J.; 2011: 8. URL: http://www.virologyj.com/content/8/1/106.

Hawkes R.A. Enhancement of the infectivity of arboviruses by specific antisera produced in domestic fowls // Aust. J. Exp. Biol. Med. Sci. 1964; 43: 465-82.

Hawkes R.A., Lafferty K.J. The enhancement of virus infectivity by antibody // Virology. 1967; 33: 250-61.

He X., Sun X., Wang J., Wang X., Zhang Q., Tzipori S., Feng H. Antibody-enhanced, Fc gamma receptor-mediated endocytosis of Clostridium difficile toxin A // Inf. Immunol. 2009; 77(6): 2294-303.

Henchal E.A., McCown J.M., Burke D.S., Seguin M.C., Brandt W.E. Epitopic analysis of antigenic determinants on the surface of Dengue‑2 virions using monoclonal antibodies // Am. J. Trop. Med. Hyg. 1985; 34: 164-9.

Hober D., Sane F., Jaïdane Y., Riedweg K., Goffard A., Desailloud R. Immunology in the clinic review series; focus on type 1 diabetes and viruses: role of antibodies enhancing the infection with Coxsackievirus-B in the pathogenesis of type 1 diabetes // Clinical and Experimental Immunology. 2011; 168: 47-51.

Homsy J., Meyer M., Tateno M., Clarkson S., Levy J.A. The Fc and not CD4 receptor mediates antibody enhancement of HIV infection in human cells // Science. 1989; 16(244): 1357-60.

Hosie M.J., Osborne R., Reid G., Neil J.C., Jarrett O. Enhancement after feline immunodeficiency virus vaccination // Vet. Immunol. Immunopathol. 1992; 35: 191-7.

Huisman W., Karlas K.H., Siebelink K.H., Huisman R.C., de Ronde A., Francis M.J. et al. Feline immunodeficiency virus subunit vaccines that induce virus neutralizing antibodies but no protection against challenge infection // Vaccine. 1998; 16: 181-7.

Iankov I.D., Pandey M., Harvey M., Griesmann G.E., Federspiel M.J., Russell S.J. Immunoglobulin G antibody-media­ted enhancement of measles virus infection can bypass the protective antiviral immune response // J. Virol. 2006; 80(17): 8530-40.

Issel C.J., Horohov D.W., Lea D.F., Adams W.V., Hagius S.D., McManus J.M. et al. Efficacy of inactivated whole-virus and subunit vaccines in preventing infection and disease caused by equine infectious anemia virus // J. Virol. 1992; (66): 3398-408.

Jaïdane H., Hober D. Role of coxsackievirus B4 in the pathogenesis of type 1 diabetes // Diabetes Metab. 2008; 34: 537-48.

Janjua N.Z., Skowronski D.M., Hottes T.S., Osei W.,

Adams E., Petric M. et al. Seasonal influenza vaccine and increased risk of pandemic A/H1N1-related illness: first detection of the association in British Columbia, Canada // Clin. Infect. Dis. 2010; 51(9): 1017-27.

Jaume M., Yip M.S., Cheung C.Y., Leung H.L., Li P.H., Kien F. et al. Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH- and cysteine protease-independent FcγR pathway // J. Virol. 2011; 85: 10582-97.

Kantola K., Hedman L., Tanner L., Simell V., Mäkinen M., Partanen J., et al. B-Cell responses to human Bocaviruses 1-4: new insights from a childhood follow-up study. B-cell responses to human Bocaviruses 1-4: new insights from a childhood follow-up study // PLoS ONE2015; 10(9): e0139096. doi:10.1371/journal.pone.0139096.

Karmarkar M., Hule G., Cameron A., Mehta P., Khopkar U., Hase N., Sriprakash K. Antibodies to group A streptococcal virulence factors, SIC and DRS, increase predilection to GAS pyoderma // BMC Infectious Diseases. 2015; 15: 113: Dоі: 10.1186/s12879-015-0857-4.

Kietzell K., Pozzuto T., Heilbronn R., Grцssl T., Fechner H., Wegera S. Antibody-mediated enhancement of Parvovirus B19 uptake into endothelial cells vediated by a receptor for complement factor C1q // J. Virol. 2014; 88(14): 8102-15.

Kim H.W., Canchola J.G., Brandt C.D. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine // Am. J. Epidemiol. 1969; 89: 422-34.

Kim J.H, Skountzou I., Compans R., Jacob J. Original antigenic sin responses to influenza viruses // J. Immunol. 2009; 183: 3294-301.

Kim J.H., Davis W.G., Sambhara S., Jacob J. Strategies to alleviate original antigenic sin responses to influenza viruses // Proc. Natl. Acad. Sci USA. 2012; 109(34): 13751-6.

King A.A., Sands J.J., Porterfield J.S. Antibody-mediated enhancement of rabies virus infection in a mouse macrophage cell line (P388D1) // J. Gen. Virol. 1984; 65: 1091-3.

Klenerman P., Zinkernagel R.M. Original antigenic sin impairs cytotoxic T lymphocyte responses to viruses bearing variant epitopes // Nature. 1998; 394: 482-5.

Kondrashova A., Reunanen A., Romanov A., Karvonen A., Viskari H., Vesikari T. et al. A six-fold gradient in the incidence of type 1 diabetes at the eastern border of Finland // Ann Med. 2005; 37: 67-72.

Kono Y., Kobayashi K., Fukunaga Y. Serological comparison among various strains of equine infectious anemia virus // Arch. Gesamte Virusforsch. 1971; 34: 202-8.

Kreil T.R., Eibl M.M. Pre- and postexposure protection by passive immunoglobulin but no enhancement of infection with a flavivirus in a mouse model // J. Virol. 1997; 71(4): 2921-7.

Kurosu T. Quasispecies of dengue virus // Trop. Med. and Health. 2011; 39(4): 29-36.

Lai C.Y., Tsai W.Y., Lin S.R., Kao C.L., Hu H.P., King C.C., Wu H.C. et al. Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly crossreactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II // J. Virol. 2008; 82 (13): 6631-43.

Larke N., Im E.-​J., Wagner R., Williamson C., Williamson A.-​L., McMichael A.J., Hanke T. Combined single-clade candidate HIV‑1 vaccines induce T cell responses limited by multiple forms of in vivo immune interference // Eur. J. Immunol. 2007; 37: 566-77.

Leitmeyer K.C., Vaughn D.W., Watts D.M., Salas R., Villalobos I., de Chacon, Ramos C., Rico-Hesse R. Dengue virus structural differences that correlate with pathogenesis // J. Virol. 1999; 73: 4738-47.

Lidbury B.A., Mahalingam S. Specific ablation of antiviral gene expression in macrophages by antibody-dependent enhancement of Ross River virus infection // J. Virol. 2000; 74: 8376-81.

Lin C.F., Lei H.Y., Shiau A.L., Liu H.S., Yeh T.M., Chen S.H. et al. Endothelial cell apoptosis induced by antibodies against dengue virus nonstructural protein 1 via production of nitric oxide // J. Immunol. 2002; 169 (2): 657-64.

Linn M.L., Aaskov G., Suhrbier A. Antibody-dependent enhancement and persistence in macrophages of an arbovirus associated with arthritis // J. Gen. Virol. 1996; 77: 407-11.

Liu I.J., Chiu C.Y., Chen Y.C., Wu H.C. Molecular mimicry of human endothelial cell antigen by autoantibodies to nonstructural protein 1 of dengue virus // J. Biol. Chem. 2011; 286(11): 9726-36.

Locher C.P., Grant R.M., Collisson E.A., Reyes-Terbn G., Elbeik T., Kahn J.O. et al. Antibody and cellular immune responses in breakthrough infection subjects after HIV type 1 glycoprotein 120 vaccination // AIDS Res. Hum. Retroviruses. 1999; 15: 1685-9.

Ma J., Dushoff J., Earn D.J. Age-specific mortality risk from pandemic influenza // J. Theor. Biol. 2011; 288: 29-34.

Maglione P.J., Xu J., Casadevall A., Chan J. Fc gamma receptors regulate immune activation and susceptibility during Mycobacterium tuberculosis infection // J. Immunol. 2008; 180: 3329-38.

Marine W.M., Thomas J.E., Thomas J.E. Antigenic me­mory to influenza A viruses in man determined by monovalent vaccines // Postgraduate Medical Journal. 1979; 55: 98-108.

Mathew A., West K., Kalayanarooj S., Gibbons R.V., Srikiatkhachorn A., Green S. et al. B-cell responses during primary and secondary dengue virus infections in humans // J. Infect. Dis. 2011; 204: 1514-22.

Mehlhop E., Ansarah-Sobrinho C., Johnson S., Engle M., Fremont D.H., Pierson T.C., Diamond M.S. C1q Inhibits antibody-dependent enhancement of Flavivirus infection in vitro and in vivo in an IgG subclass specific manner // Cell Host Microbe. 2007; 2(6): 417-26.

Merck. Vaccination and Enrollment Are Discontinued in Phase II Trials of Merck's Investigational HIV Vaccine Candidate // News Release, 2007. URL: http://www.drugs.com/news/vaccination-enrollment-discontinued-phase-ii-trials-merck-s-investigational-hiv-vaccine-candidate‑6880.html.

Meyer K., Ait-Goughoulte M., Keck Zhen-Yong, Foung S., Ray R. Antibody-dependent enhancement of hepatitis C virus infection // J. Virol. 2008; 829(5): 2140-9.

Midgley C.M., Bajwa-Joseph M., Vasanawathana S., Limpitikul W., Wills B., Flanagan A. et al. An in-depth analysis of original antigenic sin in Dengue virus infection // J. Virol. 2011; 85 (1): 410-21.

Moghaddam A., Olszewska W., Wang B., Tregoning J.S., Helson R., Sattentau Q.J., Openshaw P.J. A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines // Nat. Med. 2006; 12905-7.

Monsalvo A.C., Batalle J.P., Lopez M.F., Krause J.C., Klemenc J., Zea J. et al. Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes // Nat. Med. 2011; 17(2): 195-9.

Muller S., Wang H., Silverman G.J., Bramlet G., Haigwood N., Khler H. B-cell abnormalities in AIDS: stable and clonally-restricted antibody response in HIV‑1 infection // Scand. J. Immunol. 1993; 38: 327-34; PMID: 7692591. URL: http://dx.doi. org/10.1111/j.1365-3083.1993.tb01734.x.

Nakayama E., Tomabechi D., Matsuno K., Kishida N., Yoshida N., Feldmann H., Takada A. Antibody-dependent enhancement of Marburg virus infection // J. Infect. Dis. 2011; 204: 978-85.

Nara P.L., Garrity R.R., Goudsmit J. Neutralization of HIV‑1: a paradox of humoral proportions // FASEB J. 1991; 5: 2437-55.

Narayan O., Griffin D.E., Clements J.E. Virus mutation during «slow infection»: temporal development and characterization of mutants of visna virus recovered from sheep // J. Gen. Virol. 1978; 41: 343-52.

Paddock C.D., Nicholson W.L., Bhatnagar J., Goldsmith C.S., Greer P.W., Hayes E.B. et al. Fatal hemorrhagic fever caused by West Nile virus in the United States // Clin. Infect. Dis. 2006; 42: 1527-35.

Parsons M.S., Muller S., Kohler H., Grant M.D., Bernard N.F. On the benefits of sin can greater understanding of the 1F7-idiotypic repertoire freeze enhance HIV vaccine development? // Human Vaccines & Immunotherapeutics 2013; 9(7): 1532-8.

Peng Y.C., Wang B., Talaat K., Karron R., Powell T.J., Zeng H. et al. Boosted influenza-specific T cell responses after H5N1 pandemic live attenuated influenza virus vaccination // Front. Immunol. 2015; 6: 287. doi: 10.3389/fimmu.2015.00287.

Pleass R.J., Ogun S.A., McGuinness D.H., van de Winkel J.G., Holder A.A., Woof J.M. Novel antimalarial antibodies highlight the importance of the antibody Fc region in mediating protection // Blood. 2003; 102(13): 4424-30.

Porter A.D., Larsen A.E., Porter H.G. The pathogenesis of Aleutian disease of mink. II. Enhancement of tissue lesions following the administration of a killed virus vaccine or passive antibody // J. Immunol. 1972; 109: 1-7.

Prabhakar B.S., Nathanson N. Acute rabies deaths mediated by antibody // Nature. 1981; 290: 590-1.

Radkowski M.T., Laskus T., Goch A., Slusarczyk J. Affinity of anti-GP41 antibody in patients infected with human immunodeficiency virus type I // Eur. J. Clin. Invest. 1993; 23(8): 455-8.

Rai C., Lei H., Lin Y., Liu H., Chen S., Chen L., Yeh T. Epitope mapping of dengue-virus-enhancing monoclonal-antibody using phage display peptide library // Am. J. Infect. Dis. 2008; 4: 76-84.

Reichert T., Chowell G., Nishiura H., Christensen R.A., McCullers J.A. Does glycosylation as a modifier of original antigenic sin explain the case age distribution and unusual toxicity in pandemic novel H1N1 influenza? // BMC Infectious Diseases 2010; 10(5). URL: http://www.biomedcentral.com/1471-2334/10/5.

Reimer L.G. Q Fever // Clin. Microbiol. Rev. 1993; 6(3): 193-8.

Robinson W.E., Montefiori D.C., Mitchell W.M. Antibody-dependent enhancement of human immunodeficiency virus type 1 infection // Lancet. 1988; 9(1): 790-4.

Sato R., Hamada N., Kashiwagi T., Imamura Y., Hara K., Nishimura M. et al. Dengue hemorrhagic fever in a Japanese tra­veler with pre-existing Japanese encephalitis virus antibody // Tropical Medicine and Health. 2015; 43(2): 85-8

Shankarappa R., Margolick J.B., Gange S., Rodrigo A.G., Upchurch D., Farzadegan H. et al. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection // J. Virology. 1999; 73(12): 10489-502.

Shannon J., Heinzen R. Adaptive immunity to the obligate Intracellular pathogen Coxiella burnetii // Immunol. Res. 2009; 43(1–3): 138-48.

Skowronski D.M., DeSerres G., Crowcroft N., Janjua N.Z., Boulianne N., Hottes T.S. et al. Association between the 2008-09 seasonal influenza vaccine and pandemic H1N1 illness during spring-summer 2009: four observational studies from Ca­nada // PLoS Med. 2010; 7(Is.4).

Stewart T.A., Hultgren B., Huang X., Pitts-Meek S., Hully J., MacLachlan N.J. Induction of type 1 diabetes by interferon-α in transgenic mice // Science. 1993; 260: 1942-46.

Stiasny K., Kiermayr S., Holzmann H., Heinz F.X. Cryptic properties of a cluster of dominant flavivirus cross-reactive antigenic sites // J. Virol. 2006; 80: 9557-68.

Takada A., Watanabe S., Okazak K., Kida H., Kawa­oka Y. Infectivity enhancing antibodies to Ebola virus glycoprotein // J. Virol. 2001; 75(5): 2324-30.

Takada A., Feldmann H., Ksiazek T.G., Kawaoka Y. Antibody-dependent enhancement of Ebola virus infection // J. Virol. 2003; 77(13): 7539-44.

Takada A., Ebihara H., Feldmann H., Geisbert T.W., Kawaoka Y. Epitopes required for antibody-dependent enhancement of Ebola virus infection // J. Infec. Dis. 2007; 196: 347-56.

Takano T., Kawakami S., Yamada S., Satoh R., Hohdatsu T. Antibody-dependent enhancement occurs upon re-infection with the identical serotype virus in feline infectious peritonitis virus infection // J. Vet. Med. Sci. 2008; 70(12): 1315-21.

Takeda A., Tuazon C.U., Ennis F.A. Antibody-enhanced infection by HIV‑1 via Fc receptor-mediated entry // Science. 1988; 242(4878): 580-3.

Tan Y., Scalfone L.K., Kongpachith S., Ju C.-H., Cai X., Lindstrom T.M. et al. Sequencing antibody repertoires provides evidence for original antigenic sin shaping the antibody response to influenza vaccination // Clin. Immunol. 2014; 151(1): 55-65.

Tang C.-​T., Liao M.-​Y., Chiu C.-Y., Shen W.-​F., Chiu C.-Y., Cheng P. et al. Generation of monoclonal antibodies against Dengue virus type 4 and identification of enhancing epitopes on envelope protein // PLoS ONE. 2015; 10(8): e0136328. doi: 10.1371/journal.pone.0136328.

Thomas H.I., Wilson S., O’Tolle C.M., Lister C.M., Saeed A.M., Watkins R.P., Morgan-Capner P. Differential maturation of avidity of IgG antibodies to gp41, p24 and p17 following infection with HIV‑1 // Clin. Exp. Immunol. 1996; 103: 185-91.

Tirado S.M., Yoon K.S. Antibody-dependent enchancement of virus infection and disease // Viral. Immunol. 2003; 164(1): 69-86.

Tsai Y.T., Chang S.Y., Lee C.N., Kao C.L. Human TLR3 recognizes Dengue virus and modulates viral replication in vitro // Cell. Microbiol. 2009; 11: 604-15.

Ubol S., Chareonsirisuthigul T., Kasisith J., Klung­thong C. Clinical isolates of Dengue virus with distinctive susceptibility to nitric oxide radical induce differential gene responses in THP‑1 cells // Virology. 2008; 376: 290-6.

Ubol S., Halstead S.B. How innate immune mechanisms contribute to antibody-enhanced viral infections // Clin. Vac. Immunol. 2010; 17(12): 1829-35.

Vennema H., De Groot R., Harbour D., Dalderup M., Gruffydd-Jones T., Horzinek M.C., Spaan W.J. Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization // J. Virol. 1990; 64: 1407-9.

Vennema H., Poland A., Foley J., Pedersen N.C. Feline infectious peritonitis viruses arise by mutation from endemic feline enteric coronaviruses // Virology. 1998; 243(1): 150-7.

Wallace M.J., Smith D.W., Broom A.K., Mackenzie J.S., Hall R.A., Shellam G.R. Antibody-dependent enhancement of Murray Valley encephalitis virus virulence in mice // J. Gen. Virol. 2003; 84(7): 1723-8.

Wang S.Z., Rushlow K.E., Issel C.J. et al. Enhancement of EIAV replication and disease by immunization with a baculovirus-expressed recombinant envelope surface glycoprotein // Virol. 1994; 199: 247-251.

Wang S.Z., Rushlow K.E., Issel C.J., Cook R.F., Coo S.J., Raabe M.L. et al. Enhancement of EIAV replication and disease by immunization with a baculovirus-expressed recombinant envelope surface glycoprotein // Virol. 1994; 199: 247-51.

Wang Y., Si L., Luo Y., Guo X., Zhou J., Fang D. et al. Replacement of pr gene with Japanese encephalitis virus pr using reverse genetics reduces antibody-dependent enhancement of dengue virus 2 infection // Appl Microbiol. Biotechnol. 2015; 99: 9685-98.

Wipasa J., Xu H., Liu X., Hirunpetcharat C., Stowers A., Good M.F. Effect of Plasmodium yoelii exposure on vaccination with the 19-kilodalton carboxyl terminus of merozoite surface protein 1 and vice versa and implications for the application of a human malaria vaccine // Infection and Immunity. 2009; 77(2): 817-24.

Xu M.H., Hadinoto V., Appanna R., Joensson K., Toh G.C., Balakrishnan T. et al. Plasmablasts generated during repeated Dengue infection are virus glycoprotein-specific and bind to multiple virus serotypes // J. Immunol. 2012; 189: 5877-85.

Yip M.S., Leung N.H.L., Cheung C.Y., Li P.H., Lee H.H.Y. et al. Antibody-dependent infection of human macrophages by severe acute respiratory syndrome coronavirus // Virol. J. 2014; 11: URL: http://www.virologyj.com/content/11/1/82.

Yoong P. Enhancement of bacterial virulence by antibody neutralization of immune-activating toxins // Virulence. 2010; 1(5): 409-13.

Yu I.M., Zhang W., Holdaway H.A., Li L., Kostyuchenko V.A., Chipman P.R. et al. Structure of the immature dengue virus at low pH primes proteolytic maturation // Science. 2008; 319 (5871): 1834-7.

Zellweger R.M., Prestwood T.R., Shresta S. Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease // Cell Host Microbe. 2010; 7: 128-39.

Zhang X., He J., Li L., Zhu X., Ke C., Ni H. et al. Serolo­gic survey of the pandemic H1N1 2009 virus in Guangdong province, China: a cross sectional study // PLoS ONE. 2011; 6(8): e23034.




DOI: https://doi.org/10.22141/2312-413x.2.11.2016.77537

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 ACTUAL INFECTOLOGY

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru